{"id":55282,"date":"2014-05-07T18:10:54","date_gmt":"2014-05-07T22:10:54","guid":{"rendered":"https:\/\/www.nationaldrugscreening.com\/?p=55282"},"modified":"2023-09-06T15:37:34","modified_gmt":"2023-09-06T20:37:34","slug":"reilly-to-serve-again-on-datia-board","status":"publish","type":"post","link":"https:\/\/www.nationaldrugscreening.com\/blogs\/reilly-to-serve-again-on-datia-board\/","title":{"rendered":"Reilly to Serve Again on DATIA Board"},"content":{"rendered":"\r\n

For Immediate Release May 8, 2014 – – –<\/strong><\/p>\r\n\r\n\r\n\r\n

Reilly to Serve Again on DATIA Board<\/strong><\/h2>\r\n\r\n\r\n\r\n

The Drug and Alcohol Testing Industry Association (DATIA merged with\u00a0NDASA<\/a>\u00a0in 2023) has again elected Joe Reilly to serve on its board of directors.\u00a0 DATIA is a national trade organization of drug and alcohol testing providers.\u00a0 Reilly will be seated as a director at the upcoming Board meeting May 27, 2014 at the Arizona Biltmore Resort.\u00a0 This will coincide with the annual DATIA national conference to be held May 28-30, 2014 also at the Arizona Biltmore Resort and Spa \u2013 Phoenix, Arizona.<\/p>\r\n\r\n\r\n\r\n

Reilly previously served as a DATIA board member from 2001 \u2013 2009 and served as Chairman of the Board from 2004 \u2013 2008.\u00a0 Under Joe\u2019s leadership, the organization grew to over 1300 members with a balanced budget and healthy reserve account becoming the dominant industry association for the drug testing industry.\u00a0 The industry magazine FOCUS was launched in 2008 as one of the highlights of Joe\u2019s four year term as Chairman.\u00a0<\/p>\r\n\r\n\r\n\r\n

With experience since 1993 in the drug and alcohol testing industry, Reilly is considered a national expert in the field of workplace drug testing.\u00a0 He regularly provides expert witness testimony, consulting and training programs in this field throughout the United States.\u00a0\u00a0 Joe stated \u201cI am excited to again be a part of DATIA\u2019s leadership to assist our new Chairman Phil Dubois and other board members in steering our association as the industry starts to again see rapid growth.\u201d<\/p>\r\n\r\n\r\n\r\n

Reilly holds executive positions with multiple companies in the drug and alcohol testing industry; Joe Reilly & Associates, USA Mobile Drug Testing and National Drug Screening.\u00a0 He works out of his offices in Melbourne, Florida residing in Indian Harbour Beach, Florida.<\/p>\r\n\r\n\r\n\r\n

The Drug and Alcohol Testing Industry Association (DATIA) was founded in 1995 as the National Association of Collection Sites, and has grown to represent over 1500 members, and expanded its scope. DATIA now represents the entire spectrum of drug and alcohol service providers including collection sites, laboratories, consortiums\/TPAs, MROs, and testing equipment manufacturers.\u00a0\u00a0\u00a0 \u00a0\u00a0<\/p>\r\n\r\n\r\n\r\n

For additional information please contact Julie Floriano at 866-843-4545 or\u00a0julie@nationaldrugscreening.com<\/a>. \u00a0 \u00a0\u00a0<\/p>\r\n","protected":false},"excerpt":{"rendered":"

For Immediate Release May 8, 2014 – – – Reilly to Serve Again on DATIA Board The Drug and Alcohol Testing Industry Association (DATIA merged with\u00a0NDASA\u00a0in 2023) has again elected Joe Reilly to serve on its board of directors.\u00a0 DATIA is a national trade organization of drug and alcohol testing providers.\u00a0 Reilly will be seated […]<\/p>\n","protected":false},"author":12,"featured_media":1113,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_seopress_robots_primary_cat":"none","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55282"}],"collection":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/comments?post=55282"}],"version-history":[{"count":1,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55282\/revisions"}],"predecessor-version":[{"id":118396,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/posts\/55282\/revisions\/118396"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media\/1113"}],"wp:attachment":[{"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/media?parent=55282"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/categories?post=55282"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nationaldrugscreening.com\/wp-json\/wp\/v2\/tags?post=55282"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}